Grant: Collaborative Health Research Projects
University of Toronto
$257,915.00
Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot
EF 2018-19
Résumé
Children born with congenital heart diseases, such as tetralogy of Fallot, often have defective*heart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed.*Surgeons can enlarge the artery and add a valve leaflet by using a patch made from*pericardial tissue from around the heart or a synthetic fabric. While this provides temporary*relief to the infant or child, the repair materials cannot grow with the patient and are prone to*scarring and calcification, leading to a lifetime of reoperations and clinical interventions for the*patient.*Here, we propose to use principles of heart valve tissue engineering to produce sheets of*living valve leaflet tissue that can be used as an alternative repair material. The sheets will be*made from stem cells from the infants own umbilical cord grown on a polyurethane mesh,*which will eventually dissolve away in the body to harmless byproducts, leaving behind a*living valve leaflet produced by the stem cells. To kickstart tissue production, we will first grow*the valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility.*Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticles*loaded with an anti-scarring drug into the tissue prior to implantation. We will test this novel*replacement tissue in pigs to assess whether the material is durable, does not scar, and*remains functional in the body.*Over the next three years, our interdisciplinary team of material scientists, heart valve*experts, and cardiac surgeons will train next-generation engineers, scientists, and surgeons*and will collaborate with our partners at SickKids Hospital and Tissue Regeneration*Therapuetics to translate this novel concept in congenital heart defect repair towards practice,*significant improvement in the current standard of care, and economic impact through*commercialization.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
508364-2017
Name nom
Simmons, Craig
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
257915
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2
Nb partie
3
Application title
Engineering Pulmonary Valve Tissue for Pediatric Patients with Tetralogy of Fallot
Keyword
NSERC
Application summary
Children born with congenital heart diseases, such as tetralogy of Fallot, often have defective*heart valves. For example, in tetralogy of Fallot, the pulmonary artery and valve are narrowed.*Surgeons can enlarge the artery and add a valve leaflet by using a patch made from*pericardial tissue from around the heart or a synthetic fabric. While this provides temporary*relief to the infant or child, the repair materials cannot grow with the patient and are prone to*scarring and calcification, leading to a lifetime of reoperations and clinical interventions for the*patient.*Here, we propose to use principles of heart valve tissue engineering to produce sheets of*living valve leaflet tissue that can be used as an alternative repair material. The sheets will be*made from stem cells from the infants own umbilical cord grown on a polyurethane mesh,*which will eventually dissolve away in the body to harmless byproducts, leaving behind a*living valve leaflet produced by the stem cells. To kickstart tissue production, we will first grow*the valve tissue in bioreactors that exercise the tissue to improve its strength and flexibility.*Most engineered valve tissue fails by scarring, so to prevent this, we will inject nanoparticles*loaded with an anti-scarring drug into the tissue prior to implantation. We will test this novel*replacement tissue in pigs to assess whether the material is durable, does not scar, and*remains functional in the body.*Over the next three years, our interdisciplinary team of material scientists, heart valve*experts, and cardiac surgeons will train next-generation engineers, scientists, and surgeons*and will collaborate with our partners at SickKids Hospital and Tissue Regeneration*Therapuetics to translate this novel concept in congenital heart defect repair towards practice,*significant improvement in the current standard of care, and economic impact through*commercialization.